Literature DB >> 35696725

Reversing the Genomic, Epigenetic, and Triple-Negative Breast Cancer-Enhancing Effects of Obesity.

Laura W Bowers1, Steven S Doerstling2, Meghana G Shamsunder3, Claire G Lineberger3, Emily L Rossi4, Stephanie A Montgomery5, Michael F Coleman3, Weida Gong1, Joel S Parker1, Anthony Howell6,7, Michelle Harvie6,7, Stephen D Hursting1,3,8.   

Abstract

The reversibility of the procancer effects of obesity was interrogated in formerly obese C57BL/6 mice that lost weight via a nonrestricted low-fat diet (LFD) or 3 distinct calorie-restricted (CR) regimens (low-fat CR, Mediterranean-style CR, or intermittent CR). These mice, along with continuously obese mice and lean control mice, were orthotopically injected with E0771 cells, a mouse model of triple-negative breast cancer. Tumor weight, systemic cytokines, and incidence of lung metastases were elevated in the continuously obese and nonrestricted LFD mice relative to the 3 CR groups. Gene expression differed between the obese and all CR groups, but not the nonrestricted LFD group, for numerous tumoral genes associated with epithelial-to-mesenchymal transition as well as several genes in the normal mammary tissue associated with hypoxia, reactive oxygen species production, and p53 signaling. A high degree of concordance existed between differentially expressed mammary tissue genes from obese versus all CR mice and a microarray dataset from overweight/obese women randomized to either no intervention or a CR diet. Assessment of differentially methylated regions in mouse mammary tissues revealed that obesity, relative to the 4 weight loss groups, was associated with significant DNA hypermethylation. However, the anticancer effects of the CR interventions were independent of their ability to reverse obesity-associated mammary epigenetic reprogramming. Taken together, these preclinical data showing that the procancer effects of obesity are reversible by various forms of CR diets strongly support translational exploration of restricted dietary patterns for reducing the burden of obesity-associated cancers. PREVENTION RELEVANCE: Obesity is an established risk and progression factor for triple-negative breast cancer (TNBC). Given rising global rates of obesity and TNBC, strategies to reduce the burden of obesity-driven TNBC are urgently needed. We report the genomic, epigenetic, and procancer effects of obesity are reversible by various calorie restriction regimens. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2022        PMID: 35696725      PMCID: PMC9444913          DOI: 10.1158/1940-6207.CAPR-22-0113

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  50 in total

1.  Postdiagnosis change in bodyweight and survival after breast cancer diagnosis.

Authors:  Patrick T Bradshaw; Joseph G Ibrahim; June Stevens; Rebecca Cleveland; Page E Abrahamson; Jessie A Satia; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon
Journal:  Epidemiology       Date:  2012-03       Impact factor: 4.822

2.  Impact of age, BMI and HbA1c levels on the genome-wide DNA methylation and mRNA expression patterns in human adipose tissue and identification of epigenetic biomarkers in blood.

Authors:  Tina Rönn; Petr Volkov; Linn Gillberg; Milana Kokosar; Alexander Perfilyev; Anna Louisa Jacobsen; Sine W Jørgensen; Charlotte Brøns; Per-Anders Jansson; Karl-Fredrik Eriksson; Oluf Pedersen; Torben Hansen; Leif Groop; Elisabet Stener-Victorin; Allan Vaag; Emma Nilsson; Charlotte Ling
Journal:  Hum Mol Genet       Date:  2015-04-10       Impact factor: 6.150

Review 3.  Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis.

Authors:  Melinda Protani; Michael Coory; Jennifer H Martin
Journal:  Breast Cancer Res Treat       Date:  2010-06-23       Impact factor: 4.872

4.  Adiposity is associated with DNA methylation profile in adipose tissue.

Authors:  Golareh Agha; E Andres Houseman; Karl T Kelsey; Charles B Eaton; Stephen L Buka; Eric B Loucks
Journal:  Int J Epidemiol       Date:  2014-12-25       Impact factor: 7.196

5.  Weight change and survival after breast cancer in the after breast cancer pooling project.

Authors:  Bette J Caan; Marilyn L Kwan; Xiao Ou Shu; John P Pierce; Ruth E Patterson; Sarah J Nechuta; Elizabeth M Poole; Candyce H Kroenke; Erin K Weltzien; Shirley W Flatt; Charles P Quesenberry; Michelle D Holmes; Wendy Y Chen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-13       Impact factor: 4.254

6.  Postdiagnosis Weight Change and Survival Following a Diagnosis of Early-Stage Breast Cancer.

Authors:  Elizabeth M Cespedes Feliciano; Candyce H Kroenke; Patrick T Bradshaw; Wendy Y Chen; Carla M Prado; Erin K Weltzien; Adrienne L Castillo; Bette J Caan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-08-26       Impact factor: 4.254

7.  Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer.

Authors:  Bette J Caan; Marilyn L Kwan; Georgina Hartzell; Adrienne Castillo; Martha L Slattery; Barbara Sternfeld; Erin Weltzien
Journal:  Cancer Causes Control       Date:  2008-08-28       Impact factor: 2.506

Review 8.  Regulation of Cellular Metabolism and Hypoxia by p53.

Authors:  Timothy J Humpton; Karen H Vousden
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

9.  Weight Loss Reversed Obesity-Induced HGF/c-Met Pathway and Basal-Like Breast Cancer Progression.

Authors:  Sneha Sundaram; Trinh L Le; Luma Essaid; Alex J Freemerman; Megan J Huang; Joseph A Galanko; Kirk K McNaughton; Katharine M Bendt; David B Darr; Melissa A Troester; Liza Makowski
Journal:  Front Oncol       Date:  2014-07-08       Impact factor: 6.244

10.  Weight loss reduces basal-like breast cancer through kinome reprogramming.

Authors:  Yuanyuan Qin; Sneha Sundaram; Luma Essaid; Xin Chen; Samantha M Miller; Feng Yan; David B Darr; Joseph A Galanko; Stephanie A Montgomery; Michael B Major; Gary L Johnson; Melissa A Troester; Liza Makowski
Journal:  Cancer Cell Int       Date:  2016-04-01       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.